4//SEC Filing
Levin Andrew David 4
Accession 0001209191-22-033210
CIK 0001768446other
Filed
May 31, 8:00 PM ET
Accepted
Jun 1, 5:07 PM ET
Size
6.3 KB
Accession
0001209191-22-033210
Insider Transaction Report
Form 4
Levin Andrew David
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-19+10,000→ 10,000 totalExercise: $3.46Exp: 2032-05-18→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
Documents
Issuer
Eliem Therapeutics, Inc.
CIK 0001768446
Entity typeother
Related Parties
1- filerCIK 0001867539
Filing Metadata
- Form type
- 4
- Filed
- May 31, 8:00 PM ET
- Accepted
- Jun 1, 5:07 PM ET
- Size
- 6.3 KB